[Skip to Content]
[Skip to Content Landing]
Views 1,587
Citations 0
Comment & Response
August 3, 2020

The Uncertain Role of Corticosteroids in the Treatment of COVID-19—Reply

Author Affiliations
  • 1Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
  • 2Department of Pulmonary Medicine, QingPu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai, China
JAMA Intern Med. Published online August 3, 2020. doi:10.1001/jamainternmed.2020.2435

In Reply In response to the concerns about survival bias and the findings regarding methylprednisolone in our Original Investigation,1 we treated methylprednisolone use as a time-dependent variable with the Cox model in the same subgroup of 84 patients. The hazard ratio of methylprednisolone use for death was 0.52 (95% CI, 0.27-1.02; P = .06), suggesting a trend toward a lower mortality.

Similarly, Ellsworth et al indicated that there was no difference in mortality between patients with acute respiratory distress syndrome who received methylprednisolone (23 of 50 [46%]) and those who did not (21 of 34 [62%]; 95% CI, –40% to 8%; P = .23). There was a trend toward a better outcome, and the nonsignificant P value might indicate that this subgroup analysis was underpowered. We followed up with patients to hospital discharge or death. We agree that the follow-up might be substantially shorter than needed to observe steroid adverse effects. As we discussed,1 the findings in our cohort study should be interpreted with caution because of potential bias, residual confounding, and the small sample size.

The role of corticosteroids in treating acute respiratory distress syndrome remains controversial and inconclusive.2 For patients with coronavirus disease 2019 (COVID-19), there are insufficient data to recommend for or against the use of systemic corticosteroids.3 Although our findings about methylprednisolone use contribute to the evidence base for the systemic corticosteroids in patients with COVID-19 and acute respiratory distress syndrome, well-designed double-blinded randomized clinical trials are needed.

Back to top
Article Information

Corresponding Author: Yuanlin Song, MD, Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, 180 Fenglin Rd, Shanghai 200032, China (ylsong70_02@163.com).

Published Online: August 3, 2020. doi:10.1001/jamainternmed.2020.2435

Conflict of Interest Disclosures: None reported.

References
1.
Wu  C, Chen  X, Cai  Y,  et al.  Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.   JAMA Intern Med. Published online March 13, 2020. doi:10.1001/jamainternmed.2020.0994PubMedGoogle Scholar
2.
Shang  L, Zhao  J, Hu  Y, Du  R, Cao  B.  On the use of corticosteroids for 2019-nCoV pneumonia.   Lancet. 2020;395(10225):683-684. doi:10.1016/S0140-6736(20)30361-5PubMedGoogle ScholarCrossref
3.
US National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. Accessed June 30, 2020. https://covid19treatmentguidelines.nih.gov/critical-care/
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×